Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 14/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433767 | 0.84 | AGTR2 (0.56) | AGTR2AGTR1 | |
| SCHEMBL21602699 | 0.84 | AGTR2 (0.48) | AGTR2AGTR1BCHEPDE4APDE4B | |
| SCHEMBL421422 | 0.84 | AGTR2 (0.56) | AGTR2AGTR1 | |
| Hydrochloric Acid SCHEMBL23780713 | 0.83 | AGTR2 (0.55) | AGTR2AGTR1 | |
| Hydrochloric Acid SCHEMBL23780714 | 0.83 | AGTR2 (0.55) | AGTR2AGTR1 | |
| SCHEMBL21602377 | 0.82 | AGTR2 (0.52) | AGTR2AGTR1 | |
| SCHEMBL17510173 | 0.82 | AGTR2 (0.52) | AGTR2AGTR1PDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL29758873 | 0.81 | AGTR2 (0.51) | AGTR2AGTR1 | |
| Hydrochloric Acid SCHEMBL28510043 | 0.81 | AGTR2 (0.51) | AGTR2AGTR1 | |
| Hydrochloric Acid SCHEMBL28510044 | 0.81 | AGTR2 (0.51) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022101-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD, (AU) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022101-A1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | REN, SUDS3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | AGTR2 75/4885AGTR1 97/4885BCHE 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.